Featured Research

from universities, journals, and other organizations

Drug Slows Progression Of Lou Gehrig's Disease

Date:
December 31, 1997
Source:
Baylor College Of Medicine
Summary:
Myotrophin, an experimental drug for Lou Gehrig's disease, appears to slow the disease's symptom progression.

HOUSTON--(Dec. 22, 1997)--Myotrophin, an experimental drug for Lou Gehrig's disease, appears to slow the disease's symptom progression.

Related Articles


Results of a nine-month study involving 266 patients at eight North American medical centers were reported in the December issue of the journal Neurology.

"Patients taking a high dose of the medication progressed 26 percent slower than patients on the placebo or inactive drug," said Dr. Eugene Lai, a neurologist at Baylor College of Medicine in Houston and lead author of the journal article. "They also experienced a slower decline in quality of life."

Lou Gehrig's disease, also called amyotrophic lateral sclerosis or ALS, involves the progressive breakdown of motor neurons, the nerve cells that control muscular activity. It causes severe muscle weakness, difficulty in speaking, swallowing and breathing, and ultimately death.

"To ALS patients, slowing progression can mean maintaining arm and leg strength longer, delaying the onset of speech problems and prolonging mobility and independence," said Dr. Stanley Appel, director of the MDA/ALS Clinic at Baylor and The Methodist Hospital and Baylor chairman of neurology.

The study drug, Myotrophin or recombinant human insulin-like growth factor-I (rhIGF-I), is a man-made form of the natural protein insulin-like growth factor-I. This protein is important for normal human growth and development.

"The growth factor may act in a variety of ways on the motor neuron, nerve and skeletal muscle. It has the ability to induce nerve sprouting and growth and to promote nerve cell survival," Appel said. "These actions are important to ALS patients."

The medication was given twice daily as a shallow injection under the skin, and participants received either a low dose, a high dose or a placebo.

Patients were evaluated monthly using the Appel ALS rating scale to assess speech and swallowing, respiratory function, arm and leg muscle strength, and arm and leg function. The Sickness Impact Profile measured participants' perceptions of their quality of life, including psychological well-being, daily living and disability.

"The drug proved to be well tolerated and simple for patients to administer," Lai said.

Treatment-related side effects were relatively mild and included injection-site inflammation, hair change, knee pain and facial swelling. Less than five percent of the patients left the study due to the side effects.

Myotrophin currently is under review and pending marketing approval by the Food and Drug Administration.


Story Source:

The above story is based on materials provided by Baylor College Of Medicine. Note: Materials may be edited for content and length.


Cite This Page:

Baylor College Of Medicine. "Drug Slows Progression Of Lou Gehrig's Disease." ScienceDaily. ScienceDaily, 31 December 1997. <www.sciencedaily.com/releases/1997/12/971231085707.htm>.
Baylor College Of Medicine. (1997, December 31). Drug Slows Progression Of Lou Gehrig's Disease. ScienceDaily. Retrieved October 30, 2014 from www.sciencedaily.com/releases/1997/12/971231085707.htm
Baylor College Of Medicine. "Drug Slows Progression Of Lou Gehrig's Disease." ScienceDaily. www.sciencedaily.com/releases/1997/12/971231085707.htm (accessed October 30, 2014).

Share This



More Health & Medicine News

Thursday, October 30, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Fauci Says Ebola Risk in US "essentially Zero"

Fauci Says Ebola Risk in US "essentially Zero"

AP (Oct. 30, 2014) NIAID Director Anthony Fauci said the risk of Ebola becoming an epidemic in the U.S. is essentially zero Thursday at the Washington Ideas Forum. He also said an Ebola vaccine will be tested in West Africa in the next few months. (Oct. 30) Video provided by AP
Powered by NewsLook.com
Nurse Defies Ebola Quarantine With Bike Ride

Nurse Defies Ebola Quarantine With Bike Ride

AP (Oct. 30, 2014) A nurse who vowed to defy Maine's voluntary quarantine for health care workers who treated Ebola patients followed through on her promise Thursday, leaving her home for an hour-long bike ride. (Oct. 30) Video provided by AP
Powered by NewsLook.com
Microsoft Launches Fitness Band After Accidental Reveal

Microsoft Launches Fitness Band After Accidental Reveal

Newsy (Oct. 30, 2014) Microsoft accidentally revealed its upcoming fitness band on Wednesday, so the company went ahead and announced it. Video provided by Newsy
Powered by NewsLook.com
Studying Effects of Music on Dementia Patients

Studying Effects of Music on Dementia Patients

AP (Oct. 30, 2014) The University of Wisconsin-Milwaukee is studying the popular Music and Memory program to see if music, which helps improve the mood of Alzheimer's patients, can also reduce the use of prescription drugs for those suffering from dementia. (Oct. 30) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

    Environment News

    Technology News



    Save/Print:
    Share:

    Free Subscriptions


    Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

    Get Social & Mobile


    Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

    Have Feedback?


    Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
    Mobile: iPhone Android Web
    Follow: Facebook Twitter Google+
    Subscribe: RSS Feeds Email Newsletters
    Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins